Hospitalized patients with COVID-19 who were treated with Veklury® (remdesivir) had significantly lower risk for mortality compared with matched controls, according to 3 retrospective real-world studies presented at the 2021 World Microbe Forum.

The 3 studies included 98,654 hospitalized patients with COVID-19. The HealthVerity and Premier Healthcare databases were used to observe treatment trends and outcomes in the US for 2 retrospective comparative studies. A third analysis compared clinical outcomes in patients receiving a 10-day course of Veklury in the extension phase of the open-label SIMPLE-Severe study ( Identifier: NCT04292899) with patients receiving standard of care in a real-world retrospective longitudinal cohort study.

In the HealthVerity analysis, findings showed that patients treated with Veklury had a statistically significant 23% lower mortality risk compared with controls, regardless of baseline oxygen requirement (hazard ratio [HR] 0.77; 95% CI, 0.73-0.81). Patients who received a 5-day course of Veklury also had a significantly greater likelihood of discharge by day 28 compared with controls (HR 1.19; 95% CI, 1.14-1.25).

In the overall analysis of the Premier study, a significantly lower risk of mortality at day 14 (HR 0.76; 95% CI, 0.70-0.83; P <.0001) and at day 28 (HR 0.89; 95% CI, 0.82-0.96; P =.003) was observed in patients treated with Veklury within the first 2 days of hospitalization compared with those who did not receive Veklury. Among Veklury-treated patients who received no oxygen, low-flow oxygen, or invasive mechanical ventilation/ECMO at baseline, a significantly lower risk of mortality was noted at both day 14 and day 28. For patients on high-flow oxygen at baseline, the risk of mortality was significantly lower at 14 days, however the difference was not found to be statistically significant at 28 days.

Continue Reading

In the SIMPLE-Severe analysis, treatment with Veklury resulted in a statistically significant 54% lower mortality risk at day 28 compared with those who did not receive Veklury, regardless of baseline oxygen requirements (HR 0.46; 95% CI, 0.39-0.54; P <.001). A significantly shorter time to discharge within 28 days was also observed in patients who completed a full 10-day course of Veklury compared with those who did not (HR 1.64; 95% CI, 1.43-1.87; P <.001). The time to discharge was not significant for patients receiving invasive mechanical ventilation or ECMO at baseline.

Veklury is currently approved for the treatment of COVID-19 in patients aged 12 years and older (weighing at least 40kg) requiring hospitalization.


Gilead’s Veklury® (remdesivir) associated with a reduction in mortality rate in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets. [press release]. Foster City, CA: Gilead Sciences, Inc.; June 21, 2021.